Frenchman sues Glaxo over drug that made him 'sex addict'

Jan 31, 2011

A French father-of-two is to take GlaxoSmithKline to court on Tuesday, alleging the British firm's drug to treat Parkinson's disease turned him into a gay sex and gambling addict.

The 51-year-old's lawyers say their client's behaviour changed radically after he was first administered the drug in 2003 for the illness, which causes tremors, slows movement and disrupts speech.

Didier Jambart, a married father-of-two who says he has attempted suicide three times, claims he became addicted to , losing the family's savings and stealing to feed his habit.

He also became a compulsive gay sex addict and began exposing himself on the Internet and cross-dressing. His risky sexual encounters led to him being raped, his lawyers said.

The behaviour stopped when he stopped taking the drugs in 2005 but by then he had been demoted in his defence ministry job and was suffering from psychological trauma resulting from his addictions, his lawyers said.

The plaintiff is seeking a total of 450,000 euros ($610,000) in damages from Glaxo, which he accuses of selling a "defective" drug, and from his neurologist for having failed to properly inform him about the drug.

The drug, Requip, has been known for years to have undesired side effects but a warning only appeared on its package insert in 2006, his lawyers said.

Glaxo said it did not wish to comment on the case.

Explore further: India's meth addiction grows as criminals tap chemical hub

add to favorites email to friend print save as pdf

Related Stories

FDA questions safety of Glaxo kidney cancer drug

Oct 01, 2009

(AP) -- Federal regulators said Thursday an experimental kidney cancer drug from GlaxoSmithKline may cause liver problems, potentially outweighing its ability to slow the disease.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

NickFun
not rated yet Jan 31, 2011
Could it be he had these tendencies to begin with?